For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2021

4 - 8 Jun 2021

Virtual, United States of America

ASCO 2021: First AI-based tool for predicting genomic subtypes of pancreatic cancer from histology slides

ASCO 2021: First AI-based tool for predicting genomic subtypes of pancreatic cancer from histology s...

ASCO 2021: New insights on sarcomatoid kidney cancer

ASCO 2021: New insights on sarcomatoid kidney cancer

ASCO 2021: Remote patient monitoring may reduce need to hospitalise cancer patients

ASCO 2021: Remote patient monitoring may reduce need to hospitalise cancer patients

ASCO 2021: Newly approved drug effective against lung cancer caused by genetic mutation

ASCO 2021: Newly approved drug effective against lung cancer caused by genetic mutation

ASCO 2021: Breast cancer patients embrace integrative health during treatment

ASCO 2021: Breast cancer patients embrace integrative health during treatment

ASCO 2021: No survival difference for frontline combination regimens in real world intermediate-risk and poor-risk clear cell RCC

ASCO 2021: No survival difference for frontline combination regimens in real world intermediate-risk...

ASCO 2021: Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma

ASCO 2021: Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma

ASCO 2021: Choice of first-line platinum regimen does not significantly impact efficacy of second-line immunotherapy in advanced bladder cancer

ASCO 2021: Choice of first-line platinum regimen does not significantly impact efficacy of second-li...

ASCO 2021: PARP inhibitor significantly improved disease-free survival in patients with high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations

ASCO 2021: PARP inhibitor significantly improved disease-free survival in patients with high-risk ea...

ASCO 2021: Post-surgery immunotherapy extends disease-free survival for select patients with kidney cancer

ASCO 2021: Post-surgery immunotherapy extends disease-free survival for select patients with kidney ...

ASCO 2021: Additional chemotherapy does not offer survival benefit for patients with locally advanced cervical cancer

ASCO 2021: Additional chemotherapy does not offer survival benefit for patients with locally advance...

ASCO 2021: Both single and dual immunotherapy regimens offer improved overall survival for select patients with advanced oesophageal cancer

ASCO 2021: Both single and dual immunotherapy regimens offer improved overall survival for select pa...

ASCO 2021: Addition of immunotherapy to standard of care first-line regimen delays disease progression in advanced nasopharyngeal carcinoma

ASCO 2021: Addition of immunotherapy to standard of care first-line regimen delays disease progressi...

ASCO 2021: Targeted radiotherapy offers new treatment option for patients previously treated for metastatic castration-resistant prostate cancer

ASCO 2021: Targeted radiotherapy offers new treatment option for patients previously treated for met...

ASCO 2021: 'Electronic nose' accurately sniffs out hard-to-detect cancers

ASCO 2021: 'Electronic nose' accurately sniffs out hard-to-detect cancers

ASCO 2021: Benefits of immunotherapy combination persist for more than six years in advanced melanoma

ASCO 2021: Benefits of immunotherapy combination persist for more than six years in advanced melanom...

ASCO 2021: Antibody drug conjugate shows promise against non-small cell lung cancer resistant to targeted therapy

ASCO 2021: Antibody drug conjugate shows promise against non-small cell lung cancer resistant to tar...

ASCO 2021: Molecular profiling of tumour tissue can benefit many young patients with cancer, study suggests

ASCO 2021: Molecular profiling of tumour tissue can benefit many young patients with cancer, study s...

ASCO 2021: Additional cycle of pembrolizumab before surgery improves response rates in locally advanced head and neck cancer

ASCO 2021: Additional cycle of pembrolizumab before surgery improves response rates in locally advan...

ASCO 2021: PET scans following initial treatment help many patients with bulky early-stage Hodgkin lymphoma avoid radiotherapy

ASCO 2021: PET scans following initial treatment help many patients with bulky early-stage Hodgkin l...

ASCO 2021: Two complete responses and response rate of 41% for people with synovial sarcoma reported at ASCO in phase 2 SPEARHEAD-1 trial

ASCO 2021: Two complete responses and response rate of 41% for people with synovial sarcoma reported...

ASCO 2021: Immunotherapy delays disease recurrence in patients with early-stage, resected non-small cell lung cancer

ASCO 2021: Immunotherapy delays disease recurrence in patients with early-stage, resected non-small ...

ASCO 2021: Dual immunotherapy regimen significantly delays disease progression in patients with advanced melanoma

ASCO 2021: Dual immunotherapy regimen significantly delays disease progression in patients with adva...

ASCO 2021: Cervical cancer rates drop; other HPV-related cancers are on the rise

ASCO 2021: Cervical cancer rates drop; other HPV-related cancers are on the rise

ASCO 2021: Metabolic inhibitor IACS-6274 shows early anti-tumour effects in underserved patients

ASCO 2021: Metabolic inhibitor IACS-6274 shows early anti-tumour effects in underserved patients

More from ecancer